Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.
Summary
Bill A06222, known as the "340B Prescription Drug Anti-Discrimination Act," aims to amend New York's public health law by prohibiting discriminatory practices against covered entities and contract pharmacies participating in the 340B drug discount program. The bill defines key terms related to the 340B program and outlines specific prohibitions against pharmaceutical manufacturers, pharmacy benefit managers, and other entities that might limit access to drugs or impose unfair conditions based on participation in the program. The intent is to ensure that entities involved in the 340B program are treated equitably and are not subjected to discriminatory practices that could hinder their ability to dispense necessary medications.
Impact
If enacted, this bill would strengthen protections for covered entities and contract pharmacies in New York, ensuring that they are not discriminated against based on their participation in the 340B program. This could lead to increased access to affordable medications for low-income and uninsured patients served by these entities. Additionally, the bill would empower the state commissioner to impose civil penalties on entities that violate these provisions, thereby enhancing enforcement mechanisms within the state's public health framework.
Sentiment
The general sentiment surrounding Bill A06222 appears to be supportive among advocates for equitable healthcare access, particularly those representing low-income populations who benefit from the 340B program. However, there may be concerns from pharmaceutical manufacturers and pharmacy benefit managers regarding the implications of the bill on their operations and profit margins, suggesting a potential divide in stakeholder perspectives.
Contention
Notable points of contention may arise from pharmaceutical manufacturers and pharmacy benefit managers who could argue that the bill imposes undue restrictions on their business practices. They may express concerns about the financial implications of being required to provide equal access to drugs without the ability to impose certain conditions. Conversely, advocates for the bill emphasize the necessity of protecting vulnerable populations from discrimination in accessing medications.
Same As
Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.
Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.
Prohibits any health insurer, pharmacy benefit manager, manufacturer or other third-party payor from discriminating against any 340B entity participating in a drug discount program.
Prohibits any health insurer, pharmacy benefit manager, manufacturer or other third-party payor from discriminating against any 340B entity participating in a drug discount program.
Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B program; prohibit. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 17757c. TIE BAR WITH: SB 95'25